Tablets & Capsules

TC0519

Issue link: https://www.e-digitaleditions.com/i/1112785

Contents of this Issue

Navigation

Page 43 of 51

42 May 2019 Tablets & Capsules ing gastric retention time. On the other hand, the low specific surface area of Di-Cafos A60 necessitates higher compaction forces to ensure sufficient tablet hardness. Tri-Cafos 50 0 is t ypically not used as the main filler in DC formu- lations but can be successfully used as an additive to common f iller materials (co-diluent). When used in tablet formulations at concentra- tions of 10 to 30 percent, its large specific surface area increases the mix t u r e's bond ing capacit y and facilitates an increase in both tablet hardness and porosity, as shown in Figures 5 and 6. Apart from calcium phosphate, the tablets contained 2 percent croscarmellose sodium as a disintegrant and 0.5 percent lubri- cant (magnesium stearate). Note that, in addition to increasing the tablet hardness, admixture of Tri- C a fo s 5 0 0 c a n in c r e a s e t a ble t matrix porosity and, consequently, significantly reduce disintegration time, as shown in Figure 7. Summary Calcium phosphates' excellent flowability and high compactibility make them ideal candidates for DC tableting processes. Since the main deformation mechanism that occurs during compression is brittle fracture, these materials are less sensitive to differences in production equipment, tableting speed, or lubricant addition. Such robustness can prove to be helpful during process scale-up. Although this article focused on the functional properties of calcium phosphates for DC tableting, coarse calcium phosphate grades can also be successfully applied in wet- or dry-granulation processes, providing the advantage of ease of handling. Finally, in addition to high bulk den- sity, calcium phosphates contain a smaller fraction of fine particles, which minimizes dust generated during weighing and sieving. T&C References 1. C. R. Rowe, P. J. Sheskey, and M . E . Q u i n n , H a n d b o o k o f Phar maceutical Excipie nts (6th ed.), enhance patient compliance, espe- cially for ped iat r ic or ge r iat r ic applications. Di-Cafos A60 can also be used to desig n dosage for ms with a density greater than that of gastric fluid that will settle in the lower part of the antrum, influenc- Di-Cafos A60 has an exception- ally high densit y and ver y low porosit y, proper ties that can be used to produce smaller tablets or caps ules, as shown in Fig ur e 4. Smaller dosage forms can increase comfor t d u r ing s wallow ing and Figure 7 Effect of tribasic calcium phosphate (Tri-Cafos 500) admixture on tablet disintegration time 10 20 30 Di-Cafos A150 +10% Tri-Cafos 500 +20% Tri-Cafos 500 +30% Tri-Cafos 500 Disintegration time (seconds) 30 25 20 15 10 5 0 Compression force (kN) Figure 6 Effect of tribasic calcium phosphate (Tri-Cafos 500) admixture on tablet porosity Porosity (%) 45 40 35 30 25 20 15 10 5 0 Compression force (kN) 10 20 30 Di-Cafos A150 +10% Tri-Cafos 500 +20% Tri-Cafos 500 +30% Tri-Cafos 500

Articles in this issue

Archives of this issue

view archives of Tablets & Capsules - TC0519